vimarsana.com

Latest Breaking News On - Shaheen alanee - Page 1 : vimarsana.com

JAVELIN Bladder 100 Trial - Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

JAVELIN Bladder 100 Trial Interviews with Experts at Conferences Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information Videos April 23, 2021 November 17, 2020 November 16, 2020 October 14, 2020 Conference Coverage Conference Highlights from Recent Conference Coverage Petros Grivas, MD, PhD In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More Yohann Loriot, MD, PhD Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 tri

COVID-19 Update: Detroit TV Stations Launch NEXTGEN TV and Motown 3 0 Test Track, Farmington Hills The Care Team Acquires InTeliCare Home Health and Hospice, and More

COVID-19 Update: Detroit TV Stations Launch NEXTGEN TV and Motown 3.0 Test Track, Farmington Hills’ The Care Team Acquires InTeliCare Home Health and Hospice, and More Here is a roundup of the latest news concerning the COVID-19 pandemic in addition to announcements from local, state, and federal governments, as well as international channels. To share a business or nonprofit story, please send us a message. Courtesy of Bridge, as of Dec. 10 Here is a roundup of the latest news concerning the COVID-19 pandemic in addition to announcements from local, state, and federal governments, as well as international channels. To share a business or nonprofit story, please send us a message.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.